Presentation is loading. Please wait.

Presentation is loading. Please wait.

Charles J. Glueck, MD, Alan Brown, MD, Anne C. Goldberg, MD, James M

Published by Modified over 6 years ago

Similar presentations

Presentation on theme: "Charles J. Glueck, MD, Alan Brown, MD, Anne C. Goldberg, MD, James M"— Presentation transcript:

1 Alirocumab in high-risk patients: Observations from the open-label expanded use program 
Charles J. Glueck, MD, Alan Brown, MD, Anne C. Goldberg, MD, James M. McKenney, PharmD, Louis Kantaros, MD, John Stewart, MSc, Joseph Elassal, MD, Andrew Koren, MD  Journal of Clinical Lipidology  Volume 12, Issue 3, Pages (May 2018) DOI: /j.jacl Copyright © 2018 National Lipid Association Terms and Conditions

2 Figure 1 Patient flow through the alirocumab expanded use program. AE, adverse event; Q2W, every 2 weeks. Journal of Clinical Lipidology  , DOI: ( /j.jacl ) Copyright © 2018 National Lipid Association Terms and Conditions

3 Figure 2 Percent changes from baseline at week 24 in LDL-C and other lipid levels on alirocumab by (A) familial hypercholesterolemia (FH) status and (B) statin comedication status. N values represent the number of patients at week 24. The overall population pool included the patient who declined to take statin; this patient was not included in the “no statins” subgroup. CI, confidence interval; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; non-HDL-C, non–high-density lipoprotein cholesterol. Journal of Clinical Lipidology  , DOI: ( /j.jacl ) Copyright © 2018 National Lipid Association Terms and Conditions

Download ppt "Charles J. Glueck, MD, Alan Brown, MD, Anne C. Goldberg, MD, James M"

Similar presentations

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated.

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated.
Lipid abnormalities in foreign-born and US-born patients in a medical group  Jawali Jaranilla, MD, MPH, Terese DeFor, MS, Gabriela Vazquez Benitez, PhD,

Lipid abnormalities in foreign-born and US-born patients in a medical group  Jawali Jaranilla, MD, MPH, Terese DeFor, MS, Gabriela Vazquez Benitez, PhD,
Patient and Physician Perspectives on Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels†  Eli.

Patient and Physician Perspectives on Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels†  Eli.
A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT)  Kwang Kon Koh, MD, PhD, FACC, Chang Wook Nam,

A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT)  Kwang Kon Koh, MD, PhD, FACC, Chang Wook Nam,
The UK Paediatric Familial Hypercholesterolaemia Register: Statin-related safety and 1- year growth data  Steve E. Humphries, PhD, FRCP, Jackie Cooper,

The UK Paediatric Familial Hypercholesterolaemia Register: Statin-related safety and 1- year growth data  Steve E. Humphries, PhD, FRCP, Jackie Cooper,
Charles R. Harper, MD, Terry A. Jacobson, MD  Mayo Clinic Proceedings 

Charles R. Harper, MD, Terry A. Jacobson, MD  Mayo Clinic Proceedings 
2013 Cholesterol Guidelines Revisited: Percent LDL Cholesterol Reduction or Attained LDL Cholesterol Level or Both for Prognosis?  Sripal Bangalore, MD,

2013 Cholesterol Guidelines Revisited: Percent LDL Cholesterol Reduction or Attained LDL Cholesterol Level or Both for Prognosis?  Sripal Bangalore, MD,
Volume 93, Issue 6, Pages (June 2018)

Volume 93, Issue 6, Pages (June 2018)
Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.
Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial.

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial.
An assessment by the Statin Liver Safety Task Force: 2014 update

An assessment by the Statin Liver Safety Task Force: 2014 update
Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY.

Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY.
Charles R. Harper, MD, Terry A. Jacobson, MD  Mayo Clinic Proceedings 

Charles R. Harper, MD, Terry A. Jacobson, MD  Mayo Clinic Proceedings 
Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients  Evan Stein, MD, Harold Bays, MD, Michael Koren,

Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients  Evan Stein, MD, Harold Bays, MD, Michael Koren,
KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update

KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update
Emerging LDL therapies: Mipomersen—antisense oligonucleotide therapy in the management of hypercholesterolemia  Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA,

Emerging LDL therapies: Mipomersen—antisense oligonucleotide therapy in the management of hypercholesterolemia  Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA,
Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial  Erik S.G. Stroes, MD, PhD, Andrey.

Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial  Erik S.G. Stroes, MD, PhD, Andrey.
Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with.

Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with.
Apolipoprotein E-containing high-density lipoprotein (HDL) modifies the impact of cholesterol-overloaded HDL on incident coronary heart disease risk:

Apolipoprotein E-containing high-density lipoprotein (HDL) modifies the impact of cholesterol-overloaded HDL on incident coronary heart disease risk:
Predictors of first-year statin medication discontinuation: A cohort study  Heli Halava, MD, Risto Huupponen, MD, PhD, Jaana Pentti, BSc, Mika Kivimäki,

Predictors of first-year statin medication discontinuation: A cohort study  Heli Halava, MD, Risto Huupponen, MD, PhD, Jaana Pentti, BSc, Mika Kivimäki,

Similar presentations

Ads by Google